According to the Zhitong Finance App, Yiling Pharmaceutical (002603.SZ) announced that Beijing Yiling Pharmaceutical Co., Ltd. (“Beijing Yiling” for short), a wholly-owned subsidiary of the company, has received a “Notice of Acceptance” issued by the State Drug Administration, and the registration application for the new drug “Xin Qitong Nose Tablets” submitted by Beijing Yiling has been officially accepted.

According to the announcement, Xinqi Nasal Medicine is a class 1.1 innovative traditional Chinese medicine drug independently developed by the company. Its functional treatment is: it boosts qi, fixes the meter, and strengthens the spleen. It is used for persistent allergic rhinitis, pulmonary spleen failure, and symptoms such as sneezing, runny nose, nasal congestion, itchy nose, self-sweating, bad wind, fatigue, lack of breath, slurred speech, etc., pale tongue, white moss, or weak pulse.